Masimo Sells Sound United to Focus on Healthcare

By Bobby Samwell • Tuesday, September 23 10:17 • Permanent Link

Masimo (NASDAQ: MASI) has announced the completion of the sale of its Sound United consumer audio business to Harman International, a wholly-owned subsidiary of Samsung Electronics Co., Ltd. The sale marks an important milestone in Masimo's efforts to focus on its core professional healthcare business.

Katie Szyman, Chief Executive Officer of Masimo, expressed confidence in the company's position to broaden its patient impact, accelerate growth, and deliver stronger margins following the completion of the sale. Masimo is prioritizing share repurchases with the proceeds from the transaction.

Masimo is a global medical technology company known for developing industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, automation, and connectivity solutions. Its Masimo SET® measure-through motion and low perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies.

Masimo SET® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals, as ranked in the 2025 Newsweek World’s Best Hospitals listing.

Masimo's mission is for its innovations to empower clinicians to transform patient care, and the company is focused on delivering value for all stakeholders as it moves forward. Following these announcements, the company's shares moved 1.21%, and are now trading at a price of $142.13. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.